

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.	
		Filing Date May 12, 2006	Group Art Unit 1644



U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1	5,877,291	04/20/1995	Mezes et al.			
	A2	6,183,744	02/06/2001	Goldenberg			
	A3	6,323,000	11/07/2001	Briggs et al.			
	A4	6,342,220	01/29/2002	Adams et al.			
	A5	6,368,596	04/09/2002	Ghetie et al.			
	A6	6,683,157	01/27/2004	Briggs et al.			
	A7	2001/0006796	07/05/2001	Briggs et al.			
	A8	2002/0193571	12/19/2002	Carter et al.			
	A9	2003/0073161	04/17/2003	Briggs et al.			
	A10	2003/0148409	08/07/2003	Rossi et al.			
	A11	2004/0091475	05/13/2004	Tsuchiya et al.			
	A12	2004/0242847	12/02/2004	Fukushima et al.			
	A13	2006/0189794	08/24/2006	Tsuchiya et al.			
	A14	2006/0275301	12/07/2006	Ozaki et al.			
	A15	2007/0003556	01/07/2007	Tsuchiya et al.			

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
*	A16	JP 7-503622	04/20/1995	Japan			See A1	
*	A17	JP 10-505231	05/26/1998	Japan			See A22	
*	A18	JP 2001-506135	05/15/2001	Japan			See A7	
*	A19	JP 2001-513999	09/11/2001	Japan			See A4	
	A20	JP 2001-518930	10/16/2001	Japan			See A26	
	A21	JP 2002-544173	12/24/2002	Japan			See A29	
	A22	WO 96/04925	02/22/1996	WIPO				
	A23	WO 97/31108	08/28/1997	WIPO			English abstract	
	A24	WO 98/28331	07/02/1998	WIPO				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.S./

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.	
		Filing Date May 12, 2006	Group Art Unit 1644

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/L.S./	A25	WO 98/41641	09/24/1998	WIPO				
/L.S./	A26	WO 98/42378	10/01/1998	WIPO				
/L.S./	A27	WO 99/02567	01/21/1999	WIPO				
	A28	WO 99/10494	03/04/1999	WIPO				
	A29	WO 00/67795	11/16/2000	WIPO				
	A30	WO 01/64713	09/07/2001	WIPO				
	A31	WO 01/66737	09/13/2001	WIPO				
	A32	WO 01/74388	10/11/2001	WIPO				
	A33	WO 01/79494	10/25/2001	WIPO			English abstract	
	A34	WO 01/97858	12/27/2001	WIPO				
	A35	WO 02/04021	01/17/2002	WIPO				
	A36	WO 02/22212	03/21/2002	WIPO				
	A37	WO 02/33072	04/25/2002	WIPO			See A9	
/L.S./	A38	WO 02/33073	04/25/2002	WIPO			See A11	
/L.S./	A39	WO 03/033654	04/24/2003	WIPO				
/L.S./	A40	WO 03/104425	12/18/2003	WIPO				
/L.S./	A41	WO 2004/033499	04/22/2004	WIPO			X	
/L.S./	A42	WO 2004/081048	09/23/2004	WIPO	Abstract only		X	
/L.S./	A43	WO 2004/087763	10/14/2004	WIPO	Abstract only		X	

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/L.S./	A44	Ballmaier et al., "c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia," <i>Blood</i> , 97:139-146 (2001)
/L.S./	A45	Brinkmann et al., "FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity," <i>Curr. Opin. Immunol.</i> , 14:569-575 (2002)
/L.S./	A46	Bruenke et al., "A recombinant bispecific single-chain Fv antibody against HLA class II and FcγRIII (CD16) triggers effective lysis of lymphoma cells," <i>Br. J. Haematol.</i> , 125:167-179 (2004)
/L.S./	A47	Clark, "CD22, a B Cell-Specific Receptor, Mediates Adhesion and Signal Transduction," <i>J. Immunol.</i> , 150:4715-4718 (1993)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.	
		Filing Date May 12, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/L.S./	A48	Co et al., "A Humanized Antibody Specific for the Platelet Integrin gpIIb/IIIa," <i>J. Immunol.</i> , 152:2968-2976 (1994)
/L.S./	A49	Daniel et al., "Induction of Apoptosis in Human Lymphocytes by Human Anti-HLA Class I Antibodies," <i>Transplantation</i> , 75:1380-1386 (2003)
/L.S./	A50	De Felice et al., "Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen class I antigens in monoclonal antibody OKT3-induced T cell proliferation," <i>J. Immunol.</i> , 139:2683-2689 (1987)
/L.S./	A51	DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy," <i>Cancer Biother. Radiopharm.</i> , 16:525-535 (2001)
/L.S./	A52	Deng et al., "An Agonist Murine Monoclonal Antibody to the Human c-Mpl Receptor Stimulates Megakaryocytopoiesis," <i>Blood</i> , 92:1981-1988 (1998)
/L.S./	A53	Ebert et al., "Expression of Metallothionein II in Intestinal Metaplasia, Dysplasia, and Gastric Cancer," <i>Cancer Res.</i> , 60:1995-2001 (2000)
/L.S./	A54	Elliott et al., "Activation of the Erythropoietin (EPO) Receptor by Bivalent Anti-EPO Receptor Antibodies," <i>J. Biol. Chem.</i> , 271:24691-24697 (1996)
/L.S./	A55	Fayen et al., "Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events," <i>Int. Immunol.</i> , 10:1347-1358 (1998)
/L.S./	A56	Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnol. Adv.</i> , 18:385-401 (2000)
/L.S./	A57	Genestier et al., "Antibodies to HLA Class I $\alpha 1$ Domain Trigger Apoptosis of CD40-Activated Human B Lymphocytes," <i>Blood</i> , 90:726-735 (1997)
/L.S./	A58	Genestier et al., "Caspase-dependent Ceramide Production in Fas- and HLA Class I-mediated Peripheral T Cell Apoptosis," <i>J. Biol. Chem.</i> , 273:5060-5066 (1998)
/L.S./	A59	Genestier et al., "Fas-Independent Apoptosis of Activated T Cells Induced by Antibodies to the HLA Class I $\alpha 1$ Domain," <i>Blood</i> , 90:3629-3639 (1997)
/L.S./	A60	Genestier et al., "T cell sensitivity to HLA class I-mediated apoptosis is dependent on interleukin-2 and interleukin-4," <i>Eur. J. Immunol.</i> , 27:495-499 (1997)
/L.S./	A61	Ghetie et al., "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , 94:7509-7514 (1997)
/L.S./	A62	Goel et al., " ^{99m} Tc-Labeled Divalent and Tetravalent CC49 Single-Chain Fv's: Novel Imaging Agents for Rapid In Vivo Localization of Human Colon Carcinoma," <i>J. Nucl. Med.</i> , 42:1519-1527 (2001)
/L.S./	A63	Goel et al., "Genetically Engineered Tetravalent Single-Chain Fv of the Pancarcinoma Monoclonal Antibody CC49: Improved Biodistribution and Potential for Therapeutic Application," <i>Cancer Res.</i> , 60:6964-6971 (2000)
/L.S./	A64	Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells," <i>Blood</i> , 84:1922-1930 (1994)
/L.S./	A65	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," <i>Proc. Natl. Acad. Sci. USA</i> , 90:6444-6448 (1993)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.	
		Filing Date May 12, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/L.S./	A66	Hu et al., "Minibody: A Novel Engineered Anti-Carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-C _H 3) Which Exhibits Rapid, High-Level Targeting of Xenografts," <i>Cancer Res.</i> , 56:3055-3061 (1996)
/L.S./	A67	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," <i>J. Immunol. Methods</i> , 231:177-189 (1999)
/L.S./	A68	Kikuchi et al., "A bivalent single-chain Fv fragment against CD47 induces apoptosis for leukemic cells," <i>Biochem. Biophys. Res. Commun.</i> , 315:912-918 (2004)
/L.S./	A69	Kimura et al., "2D7 diabody bound to the $\alpha 2$ domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells," <i>Biochem. Biophys. Res. Commun.</i> , 325:1201-1209 (2004)
/L.S./	A70	Kiprianov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies," <i>J. Mol. Biol.</i> , 330:99-111 (2003)
/L.S./	A71	Kortt et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," <i>Biomol. Eng.</i> , 18:95-108 (2001)
/L.S./	A72	Kreitman et al., "Cytotoxic Activity of Disulfide-stabilized Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) toward Fresh Malignant Cells from Patients with B-Cell Leukemias," <i>Clin. Cancer Res.</i> , 6:1476-1487 (2000)
/L.S./	A73	Kulkarni et al., "Construction of a Single-Chain Antibody Derived From 5H7, A Monoclonal Antibody Specific for a Death Signaling Domain of Human Class I Major Histocompatibility Complex," <i>Transplant. Proc.</i> , 30:1081 (1998)
/L.S./	A74	Kulkarni et al., "Programmed Cell Death Signaling Via Cell-Surface Expression of a Single-Chain Antibody Transgene," <i>Transplantation</i> , 69:1209-1217 (2000)
/L.S./	A75	Lebrun et al., "Antibodies to the Extracellular Receptor Domain Restore the Hormone-insensitive Kinase and Conformation of the Mutant Insulin Receptor Valine 382," <i>J. Biol. Chem.</i> , 268:11272-11277 (1993)
/L.S./	A76	Li et al., "The Epitope Specificity and Tissue Reactivity of Four Murine Monoclonal Anti-CD22 Antibodies," <i>Cell. Immunol.</i> , 118:85-99 (1989)
/L.S./	A77	Matsuoka et al., "A Monoclonal Antibody to the $\alpha 2$ Domain of Murine Major Histocompatibility Complex Class I that Specifically Kills Activated Lymphocytes and Blocks Liver Damage in the Concanavalin A Hepatitis Model," <i>J. Exp. Med.</i> , 198:497-503 (2003)
/L.S./	A78	Matsuoka et al., "A Novel Type of Cell Death of Lymphocytes Induced by a Monoclonal Antibody without Participation of Complement," <i>J. Exp. Med.</i> , 181:2007-2015 (1995)
/L.S./	A79	Nishii, "CD22 antibody therapy," <i>Current Therapy</i> , 20:47-50 (2001) (English translation included)
/L.S./	A80	Ohtomo et al., "Molecular Cloning and Characterization of a Surface Antigen Preferentially Overexpressed on Multiple Myeloma Cells," <i>Biochem. Biophys. Res. Commun.</i> , 258:583-591 (1999)
/L.S./	A81	Oka, "Development of Novel Immunotoxin Using Recombinant Alpha-Sarcin and Its Application Treatment of Hematopoietic Tumor," <i>Sankyo Seimei Kagaku Kenkyu Shinko Zaidan Kenkyu Hokokushu</i> , 12:46-56 (1998) (concise English explanation included)
/L.S./	A82	Ono et al., "The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cyto-toxicity," <i>Mol. Immunol.</i> , 36:387-395 (1999)
/L.S./	A83	Orita et al., "A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor," <i>Blood</i> , 105:562-566 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-153US1	Application No. 10/551,504
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hiroyuki Tsunoda et al.	
		Filing Date May 12, 2006	Group Art Unit 1644

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/L.S./	A84	Ozaki et al., "A Recombinant HLA Class I-Specific Single Chain Fv Diabody Induces Cell Death in Human Lymphoid Malignancies," <i>Blood</i> , 102:933a, Abstract No. 3474 (2003)
/L.S./	A85	Ozaki et al., "Humanized Anti-HM1.24 Antibody Mediates Myeloma Cell Cytotoxicity That Is Enhanced by Cytokine Stimulation of Effector Cells," <i>Blood</i> , 93:3922-3930 (1999)
/L.S./	A86	Ozaki et al., "Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24," <i>Blood</i> , 90:3179-3186 (1997)
/L.S./	A87	Petersen et al., "The TCR-Binding Region of the HLA Class I α_2 Domain Signals Rapid Fas-Independent Cell Death: A Direct Pathway for T Cell-Mediated Killing of Target Cells?" <i>J. Immunol.</i> , 160:4343-4352 (1998)
/L.S./	A88	Pi��tri-Rouxel et al., "The biochemical effect of the naturally occurring Trp64→ Arg mutation on human β_3 -adrenoceptor activity," <i>Eur. J. Biochem.</i> , 247:1174-1179 (1997)
/L.S./	A89	Pl��ckthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," <i>Immunotechnology</i> , 3:83-105 (1997)
/L.S./	A90	Rossi et al., "Development of New Multivalent-bispecific Agents for Pretargeting Tumor Localization and Therapy," <i>Clin. Cancer Res.</i> , 9:3886s-3896s (2003)
/L.S./	A91	Sato et al., "CD22 Is Both a Positive and Negative Regulator of B Lymphocyte Antigen Receptor Signal Transduction: Altered Signaling in CD22-Deficient Mice," <i>Immunity</i> , 5:551-562 (1996)
/L.S./	A92	Scheurle et al., "Cancer Gene Discovery Using Digital Differential Display," <i>Cancer Res.</i> , 60:4037-4043 (2000)
/L.S./	A93	Smith et al., "Inhibition of T Cell Activation by a Monoclonal Antibody Reactive Against the α_3 Domain of Human MHC Class I Molecules," <i>J. Immunol.</i> , 153:1054-1067 (1994)
/L.S./	A94	Tahtis et al., "Biodistribution Properties of ¹¹¹ Indium-labeled C-Functionalized <i>trans</i> -Cyclohexyl Diethylenetriaminepentaacetic Acid Humanized 3S193 Diabody and F(ab') ₂ Constructs in a Breast Carcinoma Xenograft Model," <i>Clin. Cancer Res.</i> , 7:1061-1072 (2001)
/L.S./	A95	Tedder et al., "CD22, a B Lymphocyte-Specific Adhesion Molecule That Regulates Antigen Receptor Signaling," <i>Annu. Rev. Immunol.</i> , 15:481-504 (1997)
/L.S./	A96	Thilenius et al., "Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants," <i>Eur. J. Immunol.</i> , 27:1108-1114 (1997)
/L.S./	A97	Woodle et al., "Anti-Human Class I α_3 Domain-Specific Monoclonal Antibody Induces Programmed Cell Death in Murine Cells Expressing Human Class I MHC Transgenes," <i>Transplant. Proc.</i> , 30:1059-1060 (1998)
/L.S./	A98	Woodle et al., "Anti-Human Class I MHC Antibodies Induce Apoptosis by a Pathway That Is Distinct from the Fas Antigen-Mediated Pathway," <i>J. Immunol.</i> , 158:2156-2164 (1997)
/L.S./	A99	Woodle et al., "Class I MHC Mediates Programmed Cell Death in Human Lymphoid Cells," <i>Transplantation</i> , 64:140-146 (1997)
/L.S./	A100	Wu et al., "Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers," <i>Immunotechnology</i> , 2:21-36 (1996)
/L.S./	A101	Xiong et al., "Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody," <i>Cancer Lett.</i> , 177:29-39 (2002)
/L.S./	A102	Xu et al., "Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver," <i>Proc. Natl. Acad. Sci. USA</i> , 98:15089-15094 (2001)

Examiner Signature /Lorraine Spector/	Date Considered 03/23/2009
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	